Clinical Takeaway
In a small study of people at clinical high risk for psychosis, a single dose of CBD was found to influence the relationship between glutamate levels in the hippocampus and brain activation in the prefrontal cortex during memory tasks. This suggests CBD may work by normalizing communication between memory and reasoning brain regions that are often disrupted in early psychosis. These findings add to growing evidence that CBD has measurable acute effects on brain chemistry and function in this high-risk population, though larger trials are needed to confirm clinical relevance.
#17 A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.
Citation: Shi Yiling et al.. A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.. Psychiatry research. Neuroimaging. 2026. PMID: 41337954.
Design: 5 Journal: 0 N: 1 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study elucidates the neurobiological mechanism by which CBD may exert protective effects in the CHR population by demonstrating that a single dose can modulate the pathological relationship between elevated hippocampal glutamate and aberrant prefrontal activation patterns associated with psychosis risk. Understanding how CBD normalizes glutamate-dependent prefrontal dysfunction in CHR individuals provides a mechanistic rationale for its continued evaluation as a preventive intervention and identifies potential biomarkers for treatment response. These findings bridge the gap between biochemical alterations and cognitive phenotypes in early psychosis, informing both the selection of CHR patients most likely to benefit from CBD and the optimization of dosing strategies for clinical application.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Small sample — underpowered for subgroup analysis
Abstract: BACKGROUND: Cannabidiol (CBD) is being studied as a potential intervention for the people at clinical high risk for psychosis (CHR), though the mechanisms underlying its effects are not fully understood. Previous studies indicate that a single dose of CBD can normalize alterations in memory-related brain activation and modulate hippocampal glutamate levels in the early stages of psychosis. This study aimed to examine the acute effects of CBD on the relationship between hippocampal glutamate levels and brain activation during verbal memory in individuals at CHR. METHODS: A total of thirty-three participants (n = 33) at CHR were randomly assigned to receive a single 600 mg dose of CBD (CHR-CBD) or a placebo capsule (CHR-PLB). Age-matched healthy controls (HC) (n = 19) received no study drugs. Participants underwent MRI scanning while performing a verbal learning task, and proton magnetic resonance spectroscopy to measure hippocampal glutamate levels. Effect of group x hippocampal glutamate interactions on brain activation was tested. RESULTS: CHR-PLB showed positive correlation between hippocampal glutamate levels and dorsolateral prefrontal cortex (dlPFC) (Pcorr. = 0.0039) activation compared to HC during both verbal encoding and recall. Under a single dose of CBD, the glutamate-dlPFC activation relationship was negative and significantly different compared to placebo in CHR individuals (Pcorr. = 0.0001) during both verbal encoding and recall. The reversed correlation in CBD group was also observed in the parahippocampal gyrus (Pcorr. = 0.0022) and amygdala (Pcorr. = 0.0019) during verbal recall. CONCLUSIONS: These findings suggest that CBD may normalise disrupted hippocampal-prefrontal glutamatergic coupling in CHR, highlighting its potential to target the neurochemical mechanisms underlying cognitive impairment.
🧠 This mechanistic neuroimaging study provides intriguing preliminary evidence that a single CBD dose may normalize hippocampal-prefrontal circuitry dysfunction in individuals at clinical high risk for psychosis, potentially by modulating glutamatergic signaling, though several important caveats warrant consideration. The sample size appears modest, acute dosing does not necessarily predict effects of sustained treatment, and the relationship between observed neurobiological changes and actual clinical outcomes (symptom progression, functional decline) remains unestablished. Additionally, baseline cannabis use history, genetic vulnerability factors, and concurrent medications are potential confounders that may influence both brain glutamate levels and treatment response. While the biological plausibility is compelling and aligns with growing interest in CBD’s neuroprotective potential, we currently lack sufficient evidence to recommend CBD as a routine preventive intervention in CHR populations outside of research settings. Clinicians evaluating CHR patients should remain aware of this emerging mechanistic work while emphasizing that individual risk stratification, family psychoeduc